<p>Hims
&amp; Hers Health, Inc. (NYSE:HIMS - 獲取免費報告) 首席財務官 Oluyemi Okupe 於 11 月 17 日星期一出售了 23,187 股 Hims
&amp; Hers Health 股票。該股票的平均售價為 36.81 美元，總交易額為 853,513.47 美元。交易後，首席財務官直接持有該公司 70,232 股股票，估值約為 2,585,239.92 美元。這代表着他們持有的股票減少了 24.82%。此次出售在證券交易委員會的備案中披露，相關信息可通過此鏈接訪問。</p>
<ul>
<li>HIMS 的股價波動如過山車。投資者應該入場嗎？</li>
</ul>
<p>Oluyemi Okupe 最近還進行了以下交易：</p>
<ul>
<li>在 11 月 17 日星期一，Oluyemi Okupe 出售了 23,187 股 Hims
&amp; Hers Health 股票。該股票的平均售價為 36.81 美元，總價值為 853,513.47 美元。</li>
<li>在 10 月 17 日星期五，Oluyemi Okupe 出售了 11,592 股 Hims
&amp; Hers Health 股票。該股票的平均售價為 57.13 美元，總價值為 662,250.96 美元。</li>
<li>在 10 月 3 日星期五，Oluyemi Okupe 出售了 11,595 股 Hims
&amp; Hers Health 股票。該股票的平均售價為 57.72 美元，總價值為 669,263.40 美元。</li>
<li>在 9 月 29 日星期一，Oluyemi Okupe 出售了 85,000 股 Hims
&amp; Hers Health 股票。該股票的平均售價為 60.20 美元，總價值為 5,117,000.00 美元。</li>
<li>在 9 月 22 日星期一，Oluyemi Okupe 出售了 23,584 股 Hims
&amp; Hers Health 股票。該股票的平均售價為 57.74 美元，總價值為 1,361,740.16 美元。</li>
<li>在 9 月 15 日星期一，Oluyemi Okupe 出售了 145,000 股 Hims
&amp; Hers Health 股票。該股票的平均售價為 55.35 美元，總交易額為 8,025,750.00 美元。</li>
<li>在 8 月 26 日星期二，Oluyemi Okupe 出售了 11,581 股 Hims
&amp; Hers Health 股票。該股票的平均售價為 43.69 美元，總交易額為 505,973.89 美元。</li>
</ul>
<p>獲取 <strong>Hims
&amp; Hers Health</strong> 的提醒：</p>
<h2>Hims</h2>
<p>&amp; Hers Health 股票下跌 1.2%</p>
<p>Hims
&amp; Hers Health 股票在星期三下跌 0.45 美元，跌至 35.81 美元。該公司的交易量為 20,738,539 股，而其平均交易量為 32,329,717 股。該股票的 50 日移動平均線為 50.12 美元，200 日移動平均線為 51.42 美元。該公司的債務與股本比率為 1.67，流動比率為 1.88，速動比率為 1.64。Hims
&amp; Hers Health, Inc. 的 12 個月低點為 21.36 美元，12 個月高點為 72.98 美元。該公司的市值為 81.5 億美元，市盈率為 66.31，市盈增長比率為 7.08，貝塔值為 2.20。</p>
<ul>
<li>為什麼 Hims
&amp; Hers 股票在第三季度業績不佳後可能是一個買入機會</li>
</ul>
<p>Hims
&amp; Hers Health (NYSE:HIMS - 獲取免費報告) 最近一次發佈季度財報是在 11 月 3 日星期一。該公司報告本季度每股收益為 0.06 美元，低於市場共識預期的 0.09 美元，差額為 0.03 美元。該公司本季度的收入為 5.9898 億美元，而市場共識預期為 5.7899 億美元。Hims
&amp; Hers Health 的淨利潤率為 6.05%，股本回報率為 24.67%。與去年同期相比，該公司的收入增長了 49.2%。在去年同期，該公司每股收益為 0.32 美元。Hims
&amp; Hers Health 已設定 2025 財年的每股收益指導。2025 財年第四季度的每股收益指導。研究分析師預測 Hims
&amp; Hers Health, Inc. 本年度每股收益將達到 0.29 美元。</p>
<p>Hims
&amp; Hers Health 宣佈其董事會已於 11 月 17 日星期一批准了一項股票回購計劃，允許公司回購 2.5 億美元的流通股。該回購授權允許公司通過公開市場購買回購最多 3% 的股票。股票回購計劃通常表明公司的董事會認為其股票被低估。</p>
<h2>機構資金流入和流出</h2>
<ul>
<li>Hims
&amp; Hers 的空頭頭寸接近歷史高點，是否應該趁機買入？</li>
</ul>
<p>一些大型投資者最近買入和賣出了該股票的股份。Farallon Capital Management LLC 在第三季度將其在 Hims
&amp; Hers Health 的持股增加了 30.8%。Farallon Capital Management LLC 目前持有該公司 10,746,852 股股票，價值 609,561,000 美元，在此期間又購買了 2,533,271 股。Invesco Ltd. 在第二季度將其在 Hims
&amp; Hers Health 的股份增加了 502.2%。Invesco Ltd. 目前持有該公司 2,552,405 股股票，價值 127,237,000 美元，在上個季度又購買了 2,128,587 股。Nuveen LLC 在第一季度獲得了 Hims
&amp; Hers Health 的新股份，價值 58,403,000 美元。Clear Street LLC 在第二季度購買了 Hims
&amp; Hers Health 的新股份，價值 83,582,000 美元。最後，挪威銀行在第二季度獲得了 Hims
&amp; Hers Health 的新股份，價值約 78,464,000 美元。機構投資者和對沖基金持有該公司 63.52% 的股份。</p>
<h2>分析師評級上調和下調</h2>
<p>多家研究公司最近發佈了關於 HIMS 的報告。瑞銀集團在 11 月 4 日的報告中對 Hims &amp; Hers Health 設定了 32.00 美元的目標價。Needham &amp; Company LLC 在 8 月 5 日的研究報告中重申了對 Hims &amp; Hers Health 股票的 “持有” 評級。BTIG Research 在 11 月 4 日的研究報告中重新發布了 “買入” 評級，並對 Hims &amp; Hers Health 股票設定了 85.00 美元的目標價。美國銀行在 11 月 4 日的研究報告中將 Hims &amp; Hers Health 股票的目標價從 28.00 美元上調至 32.00 美元，並給予該公司 “表現不佳” 的評級。最後，Zacks Research 在 8 月 19 日的研究報告中將 Hims &amp; Hers Health 股票的評級從 “強力買入” 下調至 “持有”。兩位投資分析師給予該股票 “買入” 評級，十位分析師給予 “持有” 評級，三位分析師給予 “賣出” 評級。根據 MarketBeat 的數據，該股票目前的平均評級為 “減持”，共識目標價為 45.27 美元。</p>
<p><strong>閲讀我們關於 Hims &amp; Hers Health 的最新報告</strong></p>
<h2>關於 Hims &amp; Hers Health</h2>
<p>(獲取免費報告)</p>
<p>Hims &amp; Hers Health, Inc.運營一個遠程醫療諮詢平台。它將消費者與醫療專業人員連接，使他們能夠獲得心理健康、性健康、皮膚病和初級護理的醫療服務。該公司成立於 2017 年，總部位於加利福尼亞州舊金山。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Hims &amp; Hers Health</li>
<li>為什麼投資高收益分紅股票？</li>
<li>HIMS 經歷了過山車般的旅程。投資者應該上車嗎？</li>
<li>複利是如何計算的？</li>
<li>以這三隻反彈冠軍強勢結束年末</li>
<li>如何計算期權利潤</li>
<li>諾和諾德年初至今下跌 45%，引發價格戰</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在 Hims &amp; Hers Health 嗎？</h2>
<p>在考慮 Hims &amp; Hers Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Hims &amp; Hers Health 並不在名單上。</p>
<p>雖然 Hims &amp; Hers Health 目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

HIMS

<p>Hims & Hers Health 首席財務官 Oluyemi Okupe 出售了 23,187 股，每股價格為 36.81 美元，總計 853,513.47 美元，減少了 24.82% 的持股比例。公司宣佈了一項 2.5 億美元的股票回購計劃，表明其被低估。最近的財報未能達到預期，但收入同比增長了 49.2%。該股票價格波動較大，12 個月的最低價為 21.36 美元，最高價為 72.98 美元。機構投資者正在積極交易該股票</p>

<p>Hims &amp; Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 23,187 shares of Hims &amp; Hers Health stock in a transaction on Monday, November 17th. The stock was sold at an average price of $36.81, for a total transaction of $853,513.47. Following the transaction, the chief financial officer directly owned 70,232 shares in the company, valued at approximately $2,585,239.92. This represents a 24.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this link.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health, Inc. (NYSE:HIMS - 獲取免費報告) 首席財務官 Oluyemi Okupe 於 11 月 17 日星期一出售了 23,187 股 Hims
&amp; Hers Health 股票。該股票的平均售價為 36.81 美元，總交易額為 853,513.47 美元。交易後，首席財務官直接持有該公司 70,232 股股票，估值約為 2,585,239.92 美元。這代表着他們持有的股票減少了 24.82%。此次出售在證券交易委員會的備案中披露，相關信息可通過此鏈接訪問。</p>
</div><ul>
<li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li>
</ul>
<div class="lb-trans"><ul>
<li>HIMS 的股價波動如過山車。投資者應該入場嗎？</li>
</ul>
</div><p>Oluyemi Okupe also recently made the following trade(s):</p>
<div class="lb-trans"><p>Oluyemi Okupe 最近還進行了以下交易：</p>
</div><ul>
<li>On Monday, November 17th, Oluyemi Okupe sold 23,187 shares of Hims &amp; Hers Health stock. The stock was sold at an average price of $36.81, for a total value of $853,513.47.</li>
<li>On Friday, October 17th, Oluyemi Okupe sold 11,592 shares of Hims &amp; Hers Health stock. The shares were sold at an average price of $57.13, for a total value of $662,250.96.</li>
<li>On Friday, October 3rd, Oluyemi Okupe sold 11,595 shares of Hims &amp; Hers Health stock. The stock was sold at an average price of $57.72, for a total value of $669,263.40.</li>
<li>On Monday, September 29th, Oluyemi Okupe sold 85,000 shares of Hims &amp; Hers Health stock. The shares were sold at an average price of $60.20, for a total value of $5,117,000.00.</li>
<li>On Monday, September 22nd, Oluyemi Okupe sold 23,584 shares of Hims &amp; Hers Health stock. The shares were sold at an average price of $57.74, for a total value of $1,361,740.16.</li>
<li>On Monday, September 15th, Oluyemi Okupe sold 145,000 shares of Hims &amp; Hers Health stock. The stock was sold at an average price of $55.35, for a total transaction of $8,025,750.00.</li>
<li>On Tuesday, August 26th, Oluyemi Okupe sold 11,581 shares of Hims &amp; Hers Health stock. The shares were sold at an average price of $43.69, for a total transaction of $505,973.89.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 11 月 17 日星期一，Oluyemi Okupe 出售了 23,187 股 Hims
&amp; Hers Health 股票。該股票的平均售價為 36.81 美元，總價值為 853,513.47 美元。</li>
<li>在 10 月 17 日星期五，Oluyemi Okupe 出售了 11,592 股 Hims
&amp; Hers Health 股票。該股票的平均售價為 57.13 美元，總價值為 662,250.96 美元。</li>
<li>在 10 月 3 日星期五，Oluyemi Okupe 出售了 11,595 股 Hims
&amp; Hers Health 股票。該股票的平均售價為 57.72 美元，總價值為 669,263.40 美元。</li>
<li>在 9 月 29 日星期一，Oluyemi Okupe 出售了 85,000 股 Hims
&amp; Hers Health 股票。該股票的平均售價為 60.20 美元，總價值為 5,117,000.00 美元。</li>
<li>在 9 月 22 日星期一，Oluyemi Okupe 出售了 23,584 股 Hims
&amp; Hers Health 股票。該股票的平均售價為 57.74 美元，總價值為 1,361,740.16 美元。</li>
<li>在 9 月 15 日星期一，Oluyemi Okupe 出售了 145,000 股 Hims
&amp; Hers Health 股票。該股票的平均售價為 55.35 美元，總交易額為 8,025,750.00 美元。</li>
<li>在 8 月 26 日星期二，Oluyemi Okupe 出售了 11,581 股 Hims
&amp; Hers Health 股票。該股票的平均售價為 43.69 美元，總交易額為 505,973.89 美元。</li>
</ul>
</div><p>Get <strong>Hims &amp; Hers Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Hims
&amp; Hers Health</strong> 的提醒：</p>
</div><h2>Hims &amp; Hers Health Stock Down 1.2%</h2>
<div class="lb-trans"><h2>Hims</h2>
<p>&amp; Hers Health 股票下跌 1.2%</p>
</div><p>Shares of Hims &amp; Hers Health stock traded down $0.45 on Wednesday, hitting $35.81. The company had a trading volume of 20,738,539 shares, compared to its average volume of 32,329,717. The stock has a 50-day moving average of $50.12 and a 200-day moving average of $51.42. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. Hims &amp; Hers Health, Inc. has a twelve month low of $21.36 and a twelve month high of $72.98. The firm has a market capitalization of $8.15 billion, a P/E ratio of 66.31, a P/E/G ratio of 7.08 and a beta of 2.20.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health 股票在星期三下跌 0.45 美元，跌至 35.81 美元。該公司的交易量為 20,738,539 股，而其平均交易量為 32,329,717 股。該股票的 50 日移動平均線為 50.12 美元，200 日移動平均線為 51.42 美元。該公司的債務與股本比率為 1.67，流動比率為 1.88，速動比率為 1.64。Hims
&amp; Hers Health, Inc. 的 12 個月低點為 21.36 美元，12 個月高點為 72.98 美元。該公司的市值為 81.5 億美元，市盈率為 66.31，市盈增長比率為 7.08，貝塔值為 2.20。</p>
</div><ul>
<li>Why Hims &amp; Hers Stock May Be a Buy After Mixed Q3 Results</li>
</ul>
<div class="lb-trans"><ul>
<li>為什麼 Hims
&amp; Hers 股票在第三季度業績不佳後可能是一個買入機會</li>
</ul>
</div><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, November 3rd. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.03). The company had revenue of $598.98 million during the quarter, compared to the consensus estimate of $578.99 million. Hims &amp; Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The company's revenue was up 49.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.32 earnings per share. Hims &amp; Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Research analysts predict that Hims &amp; Hers Health, Inc. will post 0.29 earnings per share for the current year.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health (NYSE:HIMS - 獲取免費報告) 最近一次發佈季度財報是在 11 月 3 日星期一。該公司報告本季度每股收益為 0.06 美元，低於市場共識預期的 0.09 美元，差額為 0.03 美元。該公司本季度的收入為 5.9898 億美元，而市場共識預期為 5.7899 億美元。Hims
&amp; Hers Health 的淨利潤率為 6.05%，股本回報率為 24.67%。與去年同期相比，該公司的收入增長了 49.2%。在去年同期，該公司每股收益為 0.32 美元。Hims
&amp; Hers Health 已設定 2025 財年的每股收益指導。2025 財年第四季度的每股收益指導。研究分析師預測 Hims
&amp; Hers Health, Inc. 本年度每股收益將達到 0.29 美元。</p>
</div><p>Hims &amp; Hers Health announced that its Board of Directors has approved a share repurchase plan on Monday, November 17th that permits the company to repurchase $250.00 million in outstanding shares. This repurchase authorization permits the company to repurchase up to 3% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's board of directors believes its stock is undervalued.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health 宣佈其董事會已於 11 月 17 日星期一批准了一項股票回購計劃，允許公司回購 2.5 億美元的流通股。該回購授權允許公司通過公開市場購買回購最多 3% 的股票。股票回購計劃通常表明公司的董事會認為其股票被低估。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><ul>
<li>Hims &amp; Hers Short Interest Nears All-Time High, Buy The Dip?</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims
&amp; Hers 的空頭頭寸接近歷史高點，是否應該趁機買入？</li>
</ul>
</div><p>A number of large investors have recently bought and sold shares of the stock. Farallon Capital Management LLC raised its position in Hims &amp; Hers Health by 30.8% in the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company's stock valued at $609,561,000 after purchasing an additional 2,533,271 shares during the period. Invesco Ltd. grew its stake in shares of Hims &amp; Hers Health by 502.2% in the second quarter. Invesco Ltd. now owns 2,552,405 shares of the company's stock valued at $127,237,000 after buying an additional 2,128,587 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Hims &amp; Hers Health in the first quarter valued at $58,403,000. Clear Street LLC purchased a new stake in shares of Hims &amp; Hers Health in the 2nd quarter valued at $83,582,000. Finally, Norges Bank acquired a new position in Hims &amp; Hers Health during the 2nd quarter worth about $78,464,000. Institutional investors and hedge funds own 63.52% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投資者最近買入和賣出了該股票的股份。Farallon Capital Management LLC 在第三季度將其在 Hims
&amp; Hers Health 的持股增加了 30.8%。Farallon Capital Management LLC 目前持有該公司 10,746,852 股股票，價值 609,561,000 美元，在此期間又購買了 2,533,271 股。Invesco Ltd. 在第二季度將其在 Hims
&amp; Hers Health 的股份增加了 502.2%。Invesco Ltd. 目前持有該公司 2,552,405 股股票，價值 127,237,000 美元，在上個季度又購買了 2,128,587 股。Nuveen LLC 在第一季度獲得了 Hims
&amp; Hers Health 的新股份，價值 58,403,000 美元。Clear Street LLC 在第二季度購買了 Hims
&amp; Hers Health 的新股份，價值 83,582,000 美元。最後，挪威銀行在第二季度獲得了 Hims
&amp; Hers Health 的新股份，價值約 78,464,000 美元。機構投資者和對沖基金持有該公司 63.52% 的股份。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調和下調</h2>
</div><p>A number of research firms recently issued reports on HIMS. UBS Group set a $32.00 price objective on Hims &amp; Hers Health in a report on Tuesday, November 4th. Needham &amp; Company LLC reaffirmed a &#34;hold&#34; rating on shares of Hims &amp; Hers Health in a research note on Tuesday, August 5th. BTIG Research reissued a &#34;buy&#34; rating and issued a $85.00 price objective on shares of Hims &amp; Hers Health in a research report on Tuesday, November 4th. Bank of America raised their target price on shares of Hims &amp; Hers Health from $28.00 to $32.00 and gave the company an &#34;underperform&#34; rating in a research report on Tuesday, November 4th. Finally, Zacks Research cut shares of Hims &amp; Hers Health from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, August 19th. Two investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of &#34;Reduce&#34; and a consensus price target of $45.27.</p>
<div class="lb-trans"><p>多家研究公司最近發佈了關於 HIMS 的報告。瑞銀集團在 11 月 4 日的報告中對 Hims &amp; Hers Health 設定了 32.00 美元的目標價。Needham &amp; Company LLC 在 8 月 5 日的研究報告中重申了對 Hims &amp; Hers Health 股票的 “持有” 評級。BTIG Research 在 11 月 4 日的研究報告中重新發布了 “買入” 評級，並對 Hims &amp; Hers Health 股票設定了 85.00 美元的目標價。美國銀行在 11 月 4 日的研究報告中將 Hims &amp; Hers Health 股票的目標價從 28.00 美元上調至 32.00 美元，並給予該公司 “表現不佳” 的評級。最後，Zacks Research 在 8 月 19 日的研究報告中將 Hims &amp; Hers Health 股票的評級從 “強力買入” 下調至 “持有”。兩位投資分析師給予該股票 “買入” 評級，十位分析師給予 “持有” 評級，三位分析師給予 “賣出” 評級。根據 MarketBeat 的數據，該股票目前的平均評級為 “減持”，共識目標價為 45.27 美元。</p>
</div><p><strong>Read Our Latest Report on Hims &amp; Hers Health</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Hims &amp; Hers Health 的最新報告</strong></p>
</div><h2>About Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>關於 Hims &amp; Hers Health</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Hims &amp; Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health, Inc.運營一個遠程醫療諮詢平台。它將消費者與醫療專業人員連接，使他們能夠獲得心理健康、性健康、皮膚病和初級護理的醫療服務。該公司成立於 2017 年，總部位於加利福尼亞州舊金山。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Hims &amp; Hers Health</li>
<li>Why Invest in High-Yield Dividend Stocks?</li>
<li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li>
<li>How is Compound Interest Calculated?</li>
<li>End the Year Strong With These 3 Comeback Champions</li>
<li>How to Calculate Options Profits</li>
<li>Down 45% Year-to-Date, Novo Nordisk Ignites a Price War</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Hims &amp; Hers Health</li>
<li>為什麼投資高收益分紅股票？</li>
<li>HIMS 經歷了過山車般的旅程。投資者應該上車嗎？</li>
<li>複利是如何計算的？</li>
<li>以這三隻反彈冠軍強勢結束年末</li>
<li>如何計算期權利潤</li>
<li>諾和諾德年初至今下跌 45%，引發價格戰</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NYSE&amp;Symbol=HIMS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Hims &amp; Hers Health 嗎？</h2>
</div><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Hims &amp; Hers Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Hims &amp; Hers Health 並不在名單上。</p>
</div><p>While Hims &amp; Hers Health currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Hims &amp; Hers Health 目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Hims & Hers Health（NYSE:HIMS）的首席財務官 Oluyemi Okupe 出售了 23,187 股股票